Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD) [0.03%]
成人生长激素缺乏症(AGHD)相关影响变化的评估和治疗：解读治疗相关影响量表-成人生长激素缺乏(TRIM-AGHD)评分的变化
Meryl Brod,Jane F Beck,Lise Højbjerre et al.
Meryl Brod et al.
Background: This study's purpose was to assess the minimal important difference (MID) for the Treatment-Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD), a patient-reported outcome measure assessing grow...
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England [0.03%]
缺乏总生存数据的情况下能否准确预测疗效？以尼伏单抗与易普利姆玛联合治疗英国晚期黑色素瘤患者为例进行的案例研究分析
D Lee,A Amadi,J Sabater et al.
D Lee et al.
Background: Nivolumab with ipilimumab (the Regimen) is the first immuno-oncology combination treatment to demonstrate long-term clinical benefit for advanced melanoma patients. We evaluated the cost effectiveness of the R...
Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0-9 Years with Pertussis in Catalonia (Spain) [0.03%]
白喉疫苗接种在降低儿童百日咳直接医疗费用中的作用研究——以西班牙加泰罗尼亚为例
Pedro Plans-Rubió,Encarna Navas,Pere Godoy et al.
Pedro Plans-Rubió et al.
Objectives: The aim of this study was to assess direct health costs in children with pertussis aged 0-9 years who were vaccinated, partially vaccinated, and unvaccinated during childhood, and to assess the association bet...
Accommodation and Health Costs of Deinstitutionalized People with Mental Illness Living in Residential Services in Brazil [0.03%]
巴西社区服务中精神疾病去机构化人员的住宿和健康费用
Denise Razzouk
Denise Razzouk
Background: Health costs are the main hindrances for expanding community mental health services. Exploring patient profiles and cost predictors may be useful for optimising financial resources. However, the deinstitutiona...
Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events [0.03%]
二级心血管事件预防的阿司匹林依从性的成本效益分析
Laurence M Djatche,Stefan Varga,Robert D Lieberthal
Laurence M Djatche
Background: Suboptimal adherence to aspirin therapy for secondary prevention of cardiovascular (CV) events is an important public health problem. Prior studies have demonstrated non-adherent patients are at higher risk of...
Systematic Review of Economic Models Used to Compare Techniques for Detecting Peripheral Arterial Disease [0.03%]
用于比较外周动脉疾病检测技术的经济学模型系统评价
Eoin Moloney,Joanne O&#x;Connor,Dawn Craig et al.
Eoin Moloney et al.
Background and objective: Peripheral arterial disease (PAD) is a common condition, in which atherosclerotic narrowing in the arteries restricts blood supply to the leg muscles. In order to support future model-based econo...
Evaluation of the Impact of an Institution-Specific Dofetilide Initiation Protocol on Mean Hospital Length of Stay and Cost for Dofetilide Initiation [0.03%]
多非利特初始化特定机构的启动协议对住院时间及费用影响评估研究
Steven P Kennedy,Hanna Iaizzo,Evgueni Fayn et al.
Steven P Kennedy et al.
Background: Dofetilide is a class III antiarrhythmic drug indicated for the conversion and maintenance of normal sinus rhythm in symptomatic patients with atrial fibrillation/atrial flutter. Delay in initiation of dofetil...
The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study [0.03%]
血液透析之前慢性肾衰竭患者的医疗费用——IRIDE观察性研究结果
Claudio Jommi,Patrizio Armeni,Margherita Battista et al.
Claudio Jommi et al.
Background: Chronic kidney disease (CKD) is an important public health problem. Most of the evidence on its costs relates to patients receiving dialysis or kidney transplants, which shows that, in these phases, CKD poses ...
Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014 [0.03%]
2型糖尿病患者人群的医疗成本变化情况（2006-2014年）：一项全国性观察研究
David Nathanson,Ugne Sabale,Jan W Eriksson et al.
David Nathanson et al.
Objective: The objective of this study was to describe healthcare resource use and cost development in Sweden during 2006-2014 in a type 2 diabetes (T2D) population receiving glucose-lowering drugs (GLDs). ...